Pressure Injury Prevention & Treatment
Advanced Solutions for the prevention and treatment of pressure injuries
- Pressure injuries can lead to longer hospital stays, higher rates of readmission, greater pain and suffering for the patient, and in some cases even premature mortality.¹ Learn more about global best practices and how 3M’s unmatched breadth of science-backed solutions for skin protection and advanced wound care can help you prevent and treat pressure injuries.
-
Data from 13,254 patients in 1,117 ICUs in 90 countries found a 59% prevalence rate of ICU-acquired pressure injury²
-
Pressure injuries can develop within six hours of sustained loading³
-
Hospital mortality rate for patients with an ICU-acquired pressure injury was found to be 22.5%²
Your partner in pressure injury prevention and treatment
-
When information and recommendations are changing rapidly, it can be difficult to keep up with the latest guidelines. 3M can be an extension of your team and help deepen your facility’s expertise through professional training and educational resources designed to meet your facility’s unique challenges.
Best practices start with effective solutions
-
In 2019, the National Pressure Injury Advisory Panel (NPIAP), European Pressure Ulcer Advisory Panel (EPUAP) and Pan Pacific Pressure Injury Alliance (PPPIA) worked with nearly 200 academic and clinical experts in the study of pressure injuries to publish international guidelines⁴ outlining assessment and education recommendations and prevention and treatment protocols, including the ideal characteristics of product solutions.
We want to help you adopt recommendations for both the prevention and treatment of pressure injuries. 3M has an unmatched breadth of versatile solutions, backed by patient-centered science, including skin protection, advanced wound care dressings and negative pressure wound therapy.
Plus, when you work with 3M, you have access to the education and training needed to support evidence-based standards and to implement safe, efficient and effective application and implementation of pressure injury solutions.
Solutions to Help Prevent Pressure Injuries
-
Skin Protection
3M™ Cavilon™ Advanced Skin Protectant
A highly durable, ultra-thin, transparent, breathable and flexible barrier for at-risk and damaged skin.
- Forms a protective barrier that helps manage friction and can help reduce risks that contribute to pressure injuries
- Waterproof – attaches to wet, weepy damaged skin
- Lasts up to seven days and wears away naturally
- Helps prevent, halt and reverse the effects of incontinence-associated dermatitis (IAD), a risk factor for pressure injuries in the sacral area.⁶*
- Single-use applicator helps reduce risk of cross-contamination
3M™ Cavilon™ Advanced Skin Protectant
*The protective barrier created a favorable environment for healing.
-
Prophylactic Foam Dressing
3M™ Tegaderm™ Silicone Foam Dressings
Provide protection from the forces that can lead to pressure injury while maintaining gentle adhesion.
- 2X longer wear time than the leading competitive silicone foam dressing when worn for seven days and lifted daily for PI inspection*
- Can be lifted and repositioned without losing adhesion
- Recent clinical research⁷ has shown these dressings help reduce tissue deformation, minimizing the effects of pressure, friction and shear**
- Supports the ideal microclimate to help reduce the potential for skin maceration⁸
- Easy application and removal
- Was found to reduce the amount of tissue exposed to strain energy density (SED) by 35.3% compared to a no-dressing control⁹
3M™ Tegaderm™ Silicone Foam Dressings
*3M data on file. Median wear times. 4x4 and 6x6 dressings, based on in vivo studies EM-13977 and EM-13978.
**3M data on file. LAB-05-385368 -
Skin Barrier
3M™ Cavilon™ No Sting Barrier Film
A barrier film ideal for routine skin protection.
- Clinically proven—over 80 publications
- Helps protect intact skin from moisture and friction
- Non-sticky formula lasts up to 72 hours and dries in 30-seconds.
- The single-use wand comes in an easy-to-open, peel down package that allows for aseptic delivery
-
Skin Cleanser
3M™ Cavilon™ No-Rinse Skin Cleanser
A liquid skin cleanser that also moisturizes.
- Gentle, hypoallergenic, pH balanced formula
- Contains gentle surfactants
- Helps control odor
- Easy-to-use spray
-
Negative Pressure Wound Therapy
V.A.C.® VERAFLO™ Therapy
V.A.C.® VERAFLO™ Therapy combines the benefits of V.A.C.® Therapy with automated topical wound solution distribution and removal to help cleanse, treat and promote wound healing.
- Allows wounds to be repetitively cleansed without the need for dressing removal
- Closed loop system helps reduce the risk of cross-contamination and exposure to body fluids
- Promotes granulation tissue formation, perfusion and the removal of exudate and infectious material
- A meta-analysis of 13 studies demonstrated fewer surgical debridements compared to control therapy (p=0.01)¹⁰
- 3M NPWT technology is supported by 1,900 peer-reviewed publications
- May use with DERMATAC™ Drape, the first silicone acrylic hybrid drape, to reduce pain during NPWT dressing changes¹¹
-
Silicone Foam Dressing3M™ Tegaderm™ Silicone Foam Dressings
Meets guideline recommendations for both pressure injury prevention and treatment.
- Absorptive foam layer is designed to wick moisture away from the skin and absorb varying levels of exudate to help minimize the disruption of healing tissue
- 2X longer wear time than the leading competitive silicone foam dressing*
- Can be lifted and repositioned without losing adhesion
- Supports the ideal microclimate to help reduce the potential for skin maceration¹⁰
- Easy application and removal
3M™ Tegaderm™ Silicone Foam Dressings
*3M data on file. Median wear times. 4x4 and 6x6 dressings, based on in vivo studies EM-13977 and EM-13978.
-
Gelling Fiber DressingKERRACEL™ Ag Dressing
Powered by patented Ag Oxysalts,™ KERRACEL™ Ag Dressing combines a carboxymethyl cellulose (CMC) gelling fiber dressing with Ag Oxysalts™ Technology. Ag Oxysalts™ (Ag3+), provides up to 6 times more power than traditional silvers (Ag1+) to reduce barriers that create a hostile wound environment in vitro.¹²
- Killed at least 99.999% (5log) of broad spectrum bacterias in vitro¹³
- Eliminated dead space at the wound bed
- Locked away exudate and bacteria in vitro¹⁴
- Designed to reduce the risk of periwound maceration¹⁴
KERRACEL™ Ag Dressing
-
Protease Modulating DressingPROMOGRAN PRISMA™ Matrix
PROMOGRAN PRISMA™ Matrix is comprised of 44% Oxidized Regenerated Cellulose (ORC), 55% Collagen, and 1% Silver-ORC, which contains 25% w/w ionically bound silver, a well-known antimicrobial agent. The powerful components of Oxidized Regenerated Cellulose (ORC) + Collagen + Silver-ORC have been shown to:
- Support granulation tissue formation
- Maintain a moist wound environment¹⁵
- Protect from bacterial bioburden in the dressing
PROMOGRAN PRISMA™ Matrix
-
High Performance Foam Dressing3M™ Tegaderm™ High Performance Foam Adhesive Dressing
Multi-layer design provides high absorbency with high breathability.
- Adapts to changing levels of exudate to maintain moisture balance for optimal wound healing
- Conformable to difficult body contours
- Dressing does not stick to wound bed thereby minimizing disruption of healing tissue
3M™ Tegaderm™ High Performance Foam Adhesive Dressing
Keep up with the latest guidelines and deepen your team's expertise through training and education designed for your facility's unique challenges.
-
References:
1. Health Research & Educational Trust (2016, January). Hospital Acquired Pressure Ulcers (HAPU) Change Package: 2016 Update. Chicago, IL: Health Research & Educational Trust. Accessed at www.hret-hen.org.
2. Labeau SO, et al. Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study. Intensive Care Med. 2020 Oct 9. doi: 10.1007/s00134-020-06234-9. Epub ahead of print. PMID: 33034686.
3. Gefen A (2008) How much time does it take to get a pressure ulcer? Integrated evidence from human, animal, and in vitro studies. Ostomy Wound Manag 54:26–28, 30‑25
4. European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Quick Reference Guide. Emily Haesler (Ed.).EPUAP/NPIAP/PPPIA:2019
5. National Pressure Injury Advisory Panel. 2014 Guidelines. Prevention and Treatment of Pressure Ulcers: A Clinical Guide. Accessed at http://www.internationalguideline.com/static/pdfs/NPUAP-EPUAP-PPPIA-CPG-2017.pdf.
6. Demarre L et al. (2015). Factors predicting the development of pressure ulcers in an at-risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial. J Adv Nurs., 71(2):391-403.
7. 3M data on file. LAB-05-385368.
8. 3M data on file. EM-05-291517.
9. Sieracki J, Wilkes R, Bennett E R, et al. (September 24, 2020) Finite Element Analysis Modeling of a Novel Silicone Dressing. Cureus 12(9): e10629. DOI 10.7759/cureus.10629
10. Gabriel A, Kim PJ, Camardo M. Frequency of surgical debridement during use of negative pressure wound therapy with instillation versus control: systematic review and meta-analysis. Poster presentation at symposium on advanced wound care spring, July 24-26, 2020.
11. Kharkar, P, PhD. Assessment of a Novel Drape Containing Acrylic and Silicone-based Adhesives When Using Negative Pressure Wound Therapy. Presented at SAWC Fall 2019, October 12-14, 2019, Las Vegas, NV 2019.
12. As demonstrated in vitro † The first electron has a pull of 0.80V; the second electron has a pull of 1.98V; the third electron has a pull of 1.8V; a traditional silver Ag1+ dressing only has a pull of 0.8V, but Ag OXYSALTS™ has a pull of 4.58V (0.8V+1.98V+1.8V); 4.58V/0.8V= 5.725x -> this is then rounded up to 6x.
13. Lemire JA, Kalan L, Gugala N, Bradu A, Turner RJ. Silver oxynitrate - an efficacious compound for the prevention and eradication of dual-species biofilms. Biofouling 2017;33(6):460-469. doi:10.1080/08927014.2017.132258
14. Crawford Healthcare. Evaluation of KerraCel Ag and Aquacel Ag Extra to sequester bacteria. February 28, 2017. CHC R543.
15 Cullen et al. A protease activity model to evaluate therapies in vitro. Poster presented at: European Wound Management Association (EWMA) 2012 Conference; May 23-25,2012; Vienna, AT.
